Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
Open Access
- 10 June 2016
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 6 (6) , e432
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Molecular mechanisms in multiple myeloma drug resistanceJournal of Clinical Pathology, 2015
- Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du MyélomeJournal of Clinical Oncology, 2014
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaBlood, 2014
- Unfolded Protein Response Signaling and Metabolic DiseasesJournal of Biological Chemistry, 2014
- Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomesAnnals of Hematology, 2013
- Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Haematologica, 2011
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- Transcription factor MIST1 in terminal differentiation of mouse and human plasma cellsPhysiological Genomics, 2011
- High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access programBritish Journal of Haematology, 2008